Google
×
Feb 3, 2021 · The cyclic peptide ALRN6924, developed to target and inhibit p53:MDM2 and p53:MDMX interactions inside cells and reactivate the tumor suppressor ...
Peptides are being developed as targeted anticancer drugs to modulate cytosolic protein-protein interactions involved in cancer progression.
The cyclic peptide ALRN6924, developed to target and inhibit p53:MDM2 and p53:MDMX interactions inside cells and reactivate the tumor suppressor properties of ...
We identified two angler peptides, cTAT-KD3 and cR10-KD3, able to activate the p53 pathway in cancer cells. cTAT-KD3 entered cells via endocytic pathways, ...
Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells. https://doi.org/10.1021/acschembio.0c00988 ·.
Feb 3, 2021 · Peptides are being developed as targeted anticancer drugs to modulate cytosolic protein-protein interactions involved in cancer progression.
$29.90
We identified two angler peptides, cTAT-KD3 and cR10-KD3, able to activate the p53 pathway in cancer cells. cTAT-KD3 entered cells via endocytic pathways, ...
People also ask
Feb 27, 2023 · Angler peptides were synthesized by conjugating cell-penetrating peptides with the cell-impermeable peptide inhibitor of MDM2-p53/MDMX-p53, KD3.
Loewer, et al. Angler peptides: macrocyclic conjugates inhibit p53:MDM2/X interactions and activate apoptosis in cancer cells. ACS Chem Biol, 16 (2021), pp ...
May 6, 2024 · Macrocyclic peptides have shown promise as effective agents against cancer. These peptides possess unique features such as moderate sizes, ...